Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (TLX) Revenue
Annual & quarterly revenue history · segment & region breakdown
TLX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsTelix Pharmaceuticals Limited trailing twelve-month (TTM) revenue is $2.00B, an increase of 53.91% year-over-year from $1.21B in FY2025.
Revenue trend
2025 – 1999 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.21B | +$0.42B | +53.91% |
| 2024-12-31 | $0.78B | +$0.28B | +55.85% |
| 2023-12-31 | $0.50B | +$0.34B | +213.90% |
| 2022-12-31 | $0.16B | +$0.15B | +2007.64% |
| 2021-12-31 | $0.01B | +$0.00B | +45.71% |
| 2020-12-31 | $0.01B | +$0.00B | +49.58% |
| 2019-12-31 | $0.00B | +$0.00B | +1685.88% |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare TLX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Telix Pharmaceuticals Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Telix Pharmaceuticals Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Telix Pharmaceuticals Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
TLX revenue · 5 questionsTLX's trailing twelve-month (TTM) revenue is $2.00B. That is an increase of 53.91% year-over-year from $1.21B in FY2025.
▸ Source: FMP · Telix Pharmaceuticals Limited SEC filings · GAAP · Telix Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026